EC approves AUBAGIO® for use in RMS

In Another regulatory milestone, Aubagio® (Teriflunomide) was approved by the European Commission (EC) for use in the treatment of Relapsing Multiple Sclerosis (RMS).

For more info on Aubagio and Mutliple Scelrosis please click on the below link:
http://en.sanofi.com/Images/33587_20130830_aubagio2_en.pdf